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Abstract
The striatum is the main input structure of the basal ganglia. Distinct striatal subfields are involved in voluntary movement
generation and cognitive and emotional tasks, but little is known about the morphological and molecular differences of
striatal subregions. The ventrolateral subfield of the striatum (VLS) is the orofacial projection field of the sensorimotor
cortex and is involved in the development of orofacial dyskinesias, involuntary chewing-like movements that often
accompany long-term neuroleptic treatment. The biological basis for this particular vulnerability of the VLS is not known.
Potassium channels are known to be strategically localized within the striatum. In search of possible molecular correlates of
the specific vulnerability of the VLS, we analyzed the expression of voltage-gated potassium channels in rodent and primate
brains using qPCR, in situ hybridization, and immunocytochemical single and double staining. Here we describe a novel,
giant, non-cholinergic interneuron within the VLS. This neuron coexpresses the vesicular GABA transporter, the calcium-
binding protein parvalbumin (PV), and the Kv3.3 potassium channel subunit. This novel neuron is much larger than PV
neurons in other striatal regions, displays characteristic electrophysiological properties, and, most importantly, is restricted to
the VLS. Consequently, the giant striatal Kv3.3-expressing PV neuron may link compromised Kv3 channel function and
VLS-based orofacial dyskinesias.
Introduction
The basal ganglia comprise a group of subcortical nuclei
forming neuronal connectional loops beginning and ending
in the cortex, via relays in the caudate putamen, pallidum,
and thalamus [1]. Basal ganglia are well known for their
contribution to voluntary movement generation [2, 3].
Neurological disorders, including Parkinson’s and Hun-
tingtons’s disease, arise from pathologies in these circuits
[4]. Additionally, the basal ganglia contribute to behavioral
patterns [5] and emotional states [3]. Consequently, the
dysfunction of basal ganglia circuits also has been reported
in psychiatric disorders [6–9].
The main input receiving structure of the basal ganglia is
the striatum consisting of the caudate nucleus and the
putamen, which in higher mammals, but not rodents, are
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separated by the internal capsule. The striatum is divided
into functionally distinct subfields. The lateral striatum is
the input region for sensorimotor loops and reflects the
topography of the cortical homunculus. The ventrolateral
striatum (VLS) is the orofacial target field of that homun-
culus with functional relevance for food intake related,
reward-associated behavior, and for facial expressions cor-
responding to emotions [10–13]. Inputs to the VLS include
fibers from temporal lobe, sensorimotor cortex, amygdala,
and perirhinal and insular areas relevant to food intake and
taste [14–16]. Orofacial dyskinetic and dystonic movements
common to several CNS diseases and drug-induced syn-
dromes, including tardive dyskinesia [17, 18], most likely
arise from dysfunction of circuits involving the VLS. A
rodent model presenting vacuous chewing movements due
to systemic administration of neuroleptic drugs [19] is often
used to study tardive dyskinesia, a side effect of neuroleptic
treatment. Additionally, pilocarpine, amphetamine, phy-
sostigmine, and acetylcholine directly injected into the
VLS, but not other stiatal regions, induce vacuous chewing
movements [17, 18, 20, 21]. General abnormalities in all
major neurotransmitter systems of the striatum including
GABA [22–24], acetylcholine [25, 26], and dopamine [27]
fail to explain the prominence of orofacial side effects fol-
lowing neuroleptic treatment.
To better understand the special vulnerability of the VLS
to neuroleptic drugs, the present study aimed to recognize
molecular features that distinguish the VLS from other
striatal areas. In this regard, potassium channels display
highly characteristic distributions in the brain and, espe-
cially, in the striatum [28–30], suggesting that they may
subserve highly specific biological functions. In this regard,
the Kv2.2 potassium channel protein and a channel-related
protein (KChIP3) recently have been used as markers for
characteristic cells in the brain [31, 32].
Consequently, the present investigation is concerned
with the distribution of Kv channel proteins in the striatum,
with a view to establishing links between these ion channels
and disturbed general motor processes within VLS, the
striatal area specifically involved in orofacial movements.
The distribution of voltage-gated (Kv) potassium channels
within the striatum is less well known than is that of, e.g.,
inwardly rectifying or other potassium channels. Disturbed
Kv channel activity is associated with motor dysfunction,
neurodegeneration, and developmental deficits. Thus, mice
with double knockout of Kv3.1 and Kv3.3 display a motor
phenotype [33–35]. Mutations of the KCNC3 gene (Kv3.3
channel protein) are involved in the adult-onset spinocer-
ebellar ataxia SCN13 [36, 37], and dysfunction in
Kv1 subunits may cause episodic ataxia [38, 39]. Auto-
antibodies against Kv channels are involved in Isaac’s
syndrome [40] and mutated Kv3 family channels may cause
neuronal death [37]. The expression of Kir2.1, Kir2.3, and
Kv2.1 channels is decreased in striatal medium-sized spiny
neurons [41] and inwardly and outwardly rectifying K+
currents are reduced in mouse models of Huntington’s
Disease [36].
Materials and methods
A more detailed version of the “Materials and methods”
section is available as Supplementary information.
Chemicals
Chemicals were obtained from Sigma, Taufkirchen, Ger-
many, if not indicated otherwise.
Animals
All animal experiments were approved by the Regional
Berlin Animal Ethics Committee and conducted in strict
accordance with the European Communities Council
directive regarding care and use of animals for experimental
procedures. Adult (250–300 g) male (5) and female (5)
Wistar rats, male Sprague Dawley (3) and Long Evans (2)
rats and 5 male adult C57BL/6 mice were obtained from an
institutional breeder (Department for Experimental Medi-
cine (FEM), Charité University Medicine Berlin). Three rats
expressing the Venus fluorescent protein under the pro-
motor of the vesicular GABA transporter (vGAT1) were
bred on a Wistar background [42]. Animals were group-
housed under controlled temperature (22 °C) and illumina-
tion (12 h cycle) with water and food ad libitum. A fore-
brain block of an adult male mouse (K-01/489) and striatal
sections of an adult male rhesus monkey (K-06/108) were
available from earlier investigations. A total number of 22
animals was included in the present experiments. None of
the selected animals subsequently was excluded from
experiments. No randomization of subjects was done.
Whole-cell patch-clamp recordings in acute slice
preparations
Diencephalic slices were prepared as previously described
[43]. For whole-cell patch-clamp recordings, slices were
transferred to a submerged recording chamber perfused with
carbogenated ACSF (in mM: 125 NaCl, 2.5 KCl, 25
NaHCO3, 1.25 NaH2PO4, 25 glucose, 1 MgCl2, 2 CaCl2, 1
Na-pyruvate, 1 Na-ascorbate) maintained at 32 ± 1 °C with
an inline heater (SuperTech, Switzerland) at a high flow rate
of 10–12 ml/min. Slices were visualized with infrared dif-
ferential contrast illumination (BX-50, Olympus, Hamburg,
Germany) under a ×40 water-immersion objective (N.A.
0.8). Epifluorescent illumination (480 nm) of Venus
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fluorescent protein expressed under the vGAT promoter
was used to pre-select giant VLS neurons, which, in turn,
were filled with biocytin during patching. Further details
have been described previously [43].
Visualization, imaging, and reconstruction of the
recorded neurons
Recorded neurons were identified post hoc as previously
described [43]. Briefly, following successful outside-out
patch formation, slices were fixed with 4% paraformalde-
hyde (PFA) in 0.1 M phosphate buffer (PB) overnight at
4 °C, washed in PB and phosphate-buffered saline (PBS; 25
mM PB, 150 mM NaCl, pH 7.4), and then blocked with
10% normal goat serum (NGS), 0.3–0.5% TritonX-100, and
0.05% NaN3 all diluted in PBS at room temperature for 1 h.
Tissue-bound biocytin was visualized with the Elite-ABC-
Complex as described below (see section
“Immunocytochemistry”).
For multiple staining experiments, slices were incubated
in primary antibodies (rabbit anti choline acetyltransferase
(ChAT), 1:1000, Chemicon, USA; mouse anti parvalbu-
mine (PV), 1:5000, Swant, Switzerland) followed by
fluorescent secondary antibodies (Alexa Fluor 488 anti-
rabbit IgG; Alexa Fluor 546 goat anti-mouse IgG, both
1:500; Invitrogen, Dunfermline, UK) and with fluorescently
conjugated streptavidin (Alexa Fluor 647; 1:500, Invitro-
gen). Washed slices were mounted on glass slides with a
polymerizing mounting medium (Fluoromount-G, Southern
Biotech, AL, USA) and a 300 µm agar spacer and
coverslipped.
Neurons were imaged with a confocal laser scanning
microscope (FluoView 1000, Olympus, Hamburg,
Germany) with a ×20 objective (N.A. 0.75; Olympus).
Image stacks were collected at a resolution of 1024 × 024 or
2048 × 2048 pixels in the xy-plane and 0.5 or 1 µm steps
between imaging planes along the z-axis. For selected
neurons, high-resolution images were obtained with a
×60 silicone oil-immersion objective (N.A. 1.3) at 2048 ×
2048 resolution and 0.05–0.1 µm steps between imaging
planes in the z-axis. Pinhole was always set to 1 Airy unit
[42]. Neurons were reconstructed offline from digitally
stitched image stacks, which were segmented and recon-
structed using semi-automatic analysis software [44]; Sim-
ple Neurite Tracer plug-in for the ImageJ/FIJI software
package; http://fiji.org].
Perfusion fixation
Rats were deeply anaesthetized by intraperitoneal injections
of a cocktail consisting of 45% ketamine (100 mg/ml;
Ketavet), 35% xylazine (20 mg/ml; Rompun) and 20%
saline, at a dose of 0.16 ml⁄100 g of body weight, supple-
mented by 200 IU heparin i. p. to avoid clogging of brain
vasculature during surgery. Subsequently, animals were
fixed via transcardial perfusion with 4% PFA, 0.05% glu-
taraldehyde, and 0.2% picric acid in 0.1 M PB, pH 7.4 [45].
Brains were removed, cryoprotected in 0.4 M sucrose for
about 4 h and in 0.8 M sucrose overnight, cut into blocks at
preselected rostrocaudal levels, shock-frozen in hexane at
−70 °C, and stored at −80 °C until used.
Quantitative PCR
Four to six 20 µm thick cryostat sections from each of six
perfusion fixed rat brains taken at the level of the anterior
Table 1 Sources and dilutions of antibodies.
Antigen Species Monoclonal Label Source Number Dilution
Kv1.1 (KCNA1) Rabbit − − Author’s lab R-94/55 1:10,000
Kv1.3 (KCNA3) Rabbit − − Author’s lab R-02/59 1:50,000
Kv3.1b (KCNC1) Rabbit − − Chemicon AB 5188 1:50,000
Kv3.2 (KCNC2) Rabbit − − Chemicon AB 5190 1:10,000
Kv3.3 (KCNC3) Rabbit − − Chemicon AB 5717 1:20,000
Kv3.4 (KCNC4) Rabbit − − Chemicon AB 5192 1:20,000
Kv4.2 (KCND2) Rabbit − − Alomone labs APC 023 1:100,000
Kv4.3 (KCND3) Rabbit − − Alomone labs APC 017 1:10,000
NO synthase, neuronal Rabbit − − Sigma N 2280 1:10,000
Choline acetyltransferase Mouse + − Chemicon MAB5270 1:50,000
Parvalbumine Rabbit − − Sigma P 3171 1:5,000,000
Neurofilament (SMI-32) Rabbit + − Sternberger monoclonals SMI 32 1:50,000
Rabbit IgG Goat − Biotin Vector, Germany BA-1000 1:2000
Mouse IgG Horse − Biotin Vector, Germany BA-9500 1:2000
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commissure were transferred to PBS. For probe generation,
six samples of the dorsolateral and the VLS each were
obtained by microscope assisted manual microdissection
[46] of the sections. Samples were then transferred into
small plastic tubes, frozen in liquid nitrogen, and kept at
−80 °C. RNAs from perfusion fixed rat brain sections were
isolated and quantitative PCR was performed using Taq-
Man assays (Applied Biosystems, Darmstdt, Germany) for
raf Kv3.1 (Rn00563433_m1, spanning exon/intron bound-
ary between exons two and three to exclude detection of
genomic contamination) and rag Kv3.3 (Rn00588870_m1,
spanning exon/intron boundary between exons one and
two) as described earlier [47].
In-situ-hybridization
For riboprobe preparation, cDNA regions containing the
sequences of rat Kv3.1 (NM_012856.1, nucleotides
658–1185 and 2787–3118) and rat Kv3.3 (NM_053997.4,
nucleotides 10–508 and 2021–2395) were PCR amplified
using Advantage Taq Polymerase mixture (Clontech,
Hamburg, Germany) and cloned into the pGEM-T vector
(Promega, Karlsruhe, Germany). DIG-labeled sense
and antisense riboprobes were prepared from SP6 and T7
promotor sites, respectively, using the DIG RNA
Labeling Kit (Roche Diagnostics, Mannheim, Germany).
In-situ-hybridization was performed as described
earlier [47].
Immunocytochemistry
Blocks of the brain containing the striatum were cut into
25 µm serial coronal sections on a cryostat, and pretreated
as described earlier [48]. Primary antibodies (Table 1)
were made in rabbit against Kv1.1 and Kv3.4 (authors
laboratory), Kv1.3 (Prof. Knaus, Innsbruck), Kv3.1b,
Kv3.2, and Kv3.3 (Millipore GmbH), Kv4.2 and Kv4.3
(Alomone Labs;), neuronal NO synthetase (Alexis bio-
chemicals), ChAT (Chemion) and PV (Sigma-Aldrich
GmbH). Mouse monoclonal antibodies were made against
and neurofilament (NF) protein and SMI-32 (Sternberger
monoclonals). Primary antibodies were followed by bio-
tinylated secondary antibodies and visualized with the
ABC complex as described earlier [48]. Long and short
diameters of Kv3.3- or ChAT-stained neurons (30 cells
each) were measured (on paper prints at 960-fold mag-
nification without correction for tissue shrinkage or ran-
dom orientation.
Fig. 1 The ventrolateral
striatum is a characteristic
striatal subfield. The VLS (A,
inset) is cell-dense with few
fiber bundles as revealed by
Nissl and Klüver–Barrera
staining of overview
micrographs (A, B; dashed
lines) and visualization of
acetylcholinesterase enzyme
activity (C, green) and
neurofilament immunostaining
(C, black). VLS also contains
fewer fiber bundles (B–D) and
more parvalbumin
immunoreactivity (D) than
adjacent striatal subfields. Bar
indicates 500 µm for all panels.
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Morphological stainings
Neurons alone or in combination with myelin sheaths were
visualized with the Nissl and Klüver–Barrera staining pro-
cedures and acetylcholinesterase (AChE) enzyme activity
was demonstrated as described earlier [49, 50].
Photographic documentation
Sections were visualized with an upright Leica DMRB light
microscope and images obtained with an Olympus SP-
55UZ high-resolution digital camera. Primary photo-
micrographs were adjusted for background and brightness
with Adobe Photoshop CS3 software (10.0) and the illus-
trations were produced with the aid of Adobe Illustrator
CS3 software (13.0).
Results
The ventrolateral striatum is a morphologically
distinct area in the mammalian striatum
The VLS (boxed field in the inset of Fig. 1A) may already
be recognized on morphological analysis following staining
with cresyl violet or the Klüver–Barrera protocol as a
Fig. 2 Members of the Kv
potassium channel family are
characteristically distributed
in the striatum of the rat.
Coronal sections through the rat
forebrain are stained for Kv-
immunorectivities using a
peroxidase/DAB procedure.
Kv4.2 immunoreactivity (A, B)
is most prominent. The dense
staining in the neuropil prohibits
the visualization of individual
neurons. Kv1.3
immunoreactivity is
considerably weaker (C).
Individual neurons can be
detected at higher magnification
(D). Staining for Kv1.1 (E) and
Kv3.1 (F, residual nuclear
reactivity is unspecific) is
prominent in interneurons. Bar
in (C) indicates 500 µm in (A–
C), and bar in (F) indicates 100
µm in (D–F).
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cell-dense region with an inconspicuous medial border
(Fig. 1A, B; dashed lines). It is distinguished from adjacent
striatal areas by its higher cell density and low number of
fiber bundles (Fig. 1C). The VLS presents as an oval field in
the rat. In mice, it appears oval in the caudal striatum, but
sickle shaped in the rostral striatum. The low density of
fiber bundles leads to a characteristic appearance even in
unstained tissue sections, which permits the identification of
the VLS under the stereomicroscope to prepare DNA for
quantitative PCR experiments.
In general, striatal interneurons are visualized after
immunocytochemical staining for nitric oxide synthase
(nNOS), PV, or combined staining for AChE and NF
immunoreactivity. No characteristic details were seen with
nNOS immunoreactivity and AChE enzyme activity alone
(data not shown). The NF immunoreactivity highlights the
low number of striatal fiber bundles and reveals a
remarkable density of fine local collaterals in the VLS
(Fig. 1C). Most strikingly, PV immunoreactivity is much
stronger in the VLS as compared to adjacent striatal regions
(Fig. 1D; Supplementary Fig. 1). This is not due to a greater
density of PV neurons in the VLS, but rather to the fact that
most of them are very big. Especially the local dendritic and
axonal arborizations of PV neurons in the VLS are much
denser as compared to PV neurons in other striatal areas,
which are much smaller and have few local processes
(Supplementary Fig. 1).
Distribution of voltage-gated potassium channels in
the VLS
The distribution of individual potassium channel proteins,
particularly members of the Kv1, Kv3, and Kv4 families,
were analyzed as possibly novel anatomical or molecular
Fig. 3 The VLS selectively has giant, Kv3.3-positive neurons. On
survey micrographs of coronal sections through the rat forebrain (inset
in A; the boxed area corresponds to C), Kv3.3 immunreactivity
appears relatively weak in the VLS (A) as compared to the somato-
sensory cortex (Par1) or ventral pallidum (VP). Also note strong axon
terminal staining in the terminal field of the lateral olfactory tract (lot).
On closer inspection the Kv3.3-immunoreactive neuropil of the VLS
(A, dashed line) is somewhat darker than surrounding areas due to
intensely Kv3.3-immunoreactive neurons (A, black arrows) and their
processes. In situ hybridization with an antisense Kv3.3 probe reveals
an intense Kv3.3 mRNA signal in neurons in the same striatal area (B,
dashed line). At higher magnifications, these are recognizable as very
large Kv3.3-immunoreactive neuronal cell bodies with stout, early
branching dendrites (C, D). Note the patchy distribution of Kv3.3-
positive axons in the striatal matrix (C). Arrowed neurons in A cor-
respond to those shown in C. The neuron arrowed in C is further
enlarged in D. Bars indicate 250 µm in (A, B), 100 µm in (C), and 20
µm in (D).
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attributes specific to the VLS. The expression of Kv4.2
immunoreactivity is very high in the striatum (Fig. 2A, B),
especially in the neuropil, throughout the entire caudate
putamen. Kv1.3 staining is considerably weaker (Fig. 2C,
D) and mostly found in somata and dendrites of medium
spiny neurons. Kv1.1 and Kv3.1 are expressed in very large
neurons (Fig. 2E, F). With respect to size, distribution, and
morphological appearance these cells strongly resemble and
likely are identical to the very large Kv3.3-positive neurons
described in the next paragraph. Thus, Kv1.1 and/or Kv3.1
may form heterooligomers with Kv3.3 in the VLS. Kv1.1/
Kv3.3 heterooligomers have not been documented so far,
but Kv3.1/3.3 herterooligomers are known [51]. Kv1.1 may
be present in addition to such oligomers at different sub-
cellular locations as has been documented for Kv1.1/1.2
oligomers and Kv3.4 in axon terminals of the cerebellar
pinceau [52]. Kv3.2 and Kv3.4 are largely absent in the
striatum (Supplementary Fig. 2A, B). Kv4.3 immunor-
eactivity is limited to presumed interneurons (Supplemen-
tary Fig. 2C, D), but whether cholinergic or GABAergic has
not been investigated.
Surprising, however, is the highly specific regional and
cellular distribution of Kv3.3 immunoreactivity (Fig. 3A,
inset; Supplementary Fig. 1) in the striatum. In the VLS,
immunoreactivity against Kv3.3 appears modest at low
magnification when compared to the somatosensory cortex
(Fig. 3A, inset). Detailed inspection, however, discloses the
presence of very large Kv3.3-positive cells in the VLS
(Fig. 3C, D) that exhibit Kv3.3 expression at the protein
(Fig. 3A) and mRNA level (Fig. 3B). Quantitative PCR data
(Supplementary Fig. 3) substantiate preferential Kv3.3
expression in the VLS as compared to the dorsal striatum. In
Fig. 4 Giant, Kv3.3-positive neurons are restricted to the VLS
along its entire rostrocaudal axis. The rostrocaudal distribution of
the novel giant striatal neurons (NGSNs) in frontal sections spaced at
400 µm through the brain of a Wistar rat is shown schematically.
Individual NGSNs are indicated by red dots. Each red dot represents
one NGSN. Bar represents 2 mm for all sections.
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all but one rat, Kv3.3 mRNA was more abundant in the
VLS than in the dorsal striatum and in 5 out of 12 animals
(rats 1, 4, 6, 7, and 12), the VLS contained more than twice
as much Kv3.3 mRNA as compared to dorsal striatum.
The Kv3.3/PV coexpressing neuron is a novel type of
giant striatal cell restricted to the VLS
Cellular localization of Kv3.3 protein in the VLS is
restricted to very large neurons (Fig. 3C, D), which at first
glance resemble giant cholinergic interneurons (but see
below). Cell bodies are oval to triangular with the long
diameter of 15.8 ± 2.1 µm (maximum 24 µm) and the
short diameter of 10.4 ± 1.3 µm (n= 30), very close
to the dimensions of cholinergic interneurons (length:
17.7 ± 2.8 µm, width: 9.8 ± 1.8 µm; n= 30). They bear three
to five stout dendrites (Fig. 3D) with an arborization field
diameter of 500–600 µm. Note the patchy distribution
(Fig. 3C) of Kv3.3-positive processes in the striatal matrix,
which may indicate specific interactions with selected input
areas or cell groups in the VLS.
Kv3.3-positive, novel giant striatal neurons (NGSNs) are
present only in the VLS (Fig. 3A, B), the striatal area with
the highest expression of PV (Fig. 1D, Supplementary
Fig. 1). Double immunofluoescence reveals that PV and
Kv3.3 are coexpressed in NGSNs (see below). The con-
spicuous restriction of Kv3.3-positive NGSNs to the VLS is
most obvious when they are schematically displayed at
Fig. 5 NGSNs are not
cholinergic. A Kv3.3-
immunopositive neuron in (A) is
devoid of ChAT-
immunoreactivity (B, arrowhead
without target). After merging
(C), red and green
immunoreactive neurons remain
distinct indicating no overlap of
immunoreactivities. In contrast
(D–F), a NGSN exhibits Kv3.3
(D, arrowhead) and parvalbumin
(E, arrowhead)
immunoreactivities (merge
shown in F, arrowhead). In
contrast, smaller parvalbumin-
positive interneurons (E, F,
arrows) do not exhibit the Kv3.3
immunoreactivity. Asterisks
indicate unspecific staining in
fiber bundles. Bar in (D)
indicates 50 µm for all panels.
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several rostrocaudal levels along the complete rostrocaudal
axis of rat brain (Fig. 4).
The presence of NGSNs in the VLS is not a spurious
effect of breed, race, or species. Counts of Kv3.3-positive
neurons in rats of different genders and strains (Wistar,
Sprague Dawley, Long Evans) did not reveal any obvious
variations in this pattern specific to a certain strain, to one of
the hemispheres, or to the gender of the animals.
In both mouse and rat, as noted, Kv3.3 immunoreactivity
appears weak in the VLS (Supplementary Fig. 4A, lower
box) when compared to the somatosensory cortex (Sup-
plementary Fig. 4A). At higher magnification it becomes
apparent that the dorsomedial striatum (Supplementary
Fig. 4A, upper box; enlarged in Supplementary Fig. 4B) is
devoid of Kv 3.3-immunopositive cell bodies. In contrast,
the mouse VLS (Supplementary Fig. 4A, lower box;
enlarged in C) contains Kv3.3-immunopositive cells (Sup-
plementary Fig. 4C, arrows), which at higher magnification
(Supplementary Fig. 4D) much resemble those observed in
the rat VLS (compare to Fig. 3D).
Our Kv3.3 antibody did not detect Kv3.3 channels
unequivocally in monkey brain (Supplementary Fig. 4E),
which, however, did exhibit very large, PV-positive neurons
restricted to the VLS (Supplementary Fig. 4F), indicating
that the NGSNs also are present in primates. Actually,
“giant, PV neurons” have been described before in the
monkey striatum, but without specifying any characteristic
striatal localization [53].
NGSNs are distinct from giant cholinergic
interneurons
The NGSNs in the VLS morphologically resemble giant
cholinergic striatal interneurons. However, they are
restricted to the VLS, while giant cholinergic interneurons,
also known as tonically active neurons (TANs), are found
throughout the entire striatum. This fact already indicates
that the Kv3.3-immunoreactive neurons, which also express
PV and GAD immunoreactivity, are distinct from the cho-
linergic interneurons.
Fig. 6 Electrophysiology
discloses a fast-spiking
phenotype for the NGSNs. A
projected 3D-reconstruction of a
NGSN from the VLS (A) shows
the somatodendritic (black) and
axonal (red) domains. The same
cell is characterized by
immunocytochemistry (B1–B4).
Note the strong co-localization
(asterisk) of biocytin labeling
(Bioc) with vGAT-YFP (green
pseudocolour) and also
parvalbumin (PV, magenta
pseudocolour), but not with
ChAT (red pseudocolour). Note
that the putative medium spiny
neuron (B1, left lower corner) is
vGAT positive but contains
neither ChAT nor PV. A large
ChAT positive cell (B2) is
vGAT and PV negative. The
NGSN in (A) responded to
depolarizing current pulses
(−500 to +1 nA, 500 ms) with
fast spiking (C), as is typical for
PV-containing interneurons. The
current-voltage relationship of
the same cell (D) discloses a low
input resistance as well as a
rectifying voltage response.
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To support this, NGSNs in the VLS were subjected to
co-immunolocalization of several transmitter markers. As
expected, large Kv3.3-immunoreactive NGSNs (Fig. 5A,
arrowhead) do not express ChAT, a cholinergic marker
protein (Fig. 5B, arrowhead without target). Cholinergic
interneurons have similar sizes and are immunoreactive for
ChAT (Fig. 5B, C, arrows). After merge, Kv3.3-positive
neurons remain green (Fig. 5C, arrowhead) and cholinergic
cells remain red (Fig. 5C, arrows) indicating no overlap of
immunoreactivitiy. In contrast, NGSNs, but not cholinergic
neurons, display Kv3.3 (Fig. 5D, arrowhead) and PV
(Fig. 5E, arrowhead) immunoreactivities (merge shown in
Fig. 5F, arrowhead). Note also that small PV-positive cells
(Fig. 5E, F, arrows) do not express the Kv3.3 channel.
Kv3.3/PV coexpressing NGSNs are distinct from giant
cholinergic interneurons also by their electrophysiological
properties
PV neurons in the striatum are known to be GABAergic
and coexpress the vesicular GABA transporter vGAT. For a
preliminary electrophysiological analysis, VLS NGSNs (n
= 6) were identified in rat brain slices under video mon-
itored infrared illumination by their typical localization in
the VLS and their large sizes as mentioned above. Six cells
were patch-clamped in the whole-cell mode, filled with
biocytin (Fig. 6), and morphologically reconstructed (n=
3). As expected, the cells displayed very large somata with
long, essentially smooth and sparsely branched dendrites.
The distal parts of the dendrites showed numerous and
prominent varicosities (Fig. 6A), which is atypical for
cholinergic interneurons [54].
VLS NGSNs (n= 6) have a mean resting potential of
−72.4 mV, similar to the value (−57.3, see Table 2) known
for the large cholinergic interneurons [55]. In contrast, input
resistance (86.8 MOhm versus 433.0MOhm, respectively)
and amplitude of after-hyperpolarization (−9.6 mV versus
−21.8 mV, respectively) differ substantially between the
NGSNs and cholinergic interneurons (Table 2). In addition,
VLS NGSNs have a short half amplitude spike width
(0.51 ms), which is considerably less than that of choli-
nergic interneurons (0.82 ms), but similar to the value found
in fast-spiking interneurons (Table 2). Furthermore, the
recorded VLS neurons displayed a spontaneous action
potential discharge frequency of 220 ± 47 Hz, which is
typical for fast-spiking interneurons. Altogether, the elec-
trophysiological results support the view that the NGSNs in
the VLS represent a novel type of fast-spiking striatal
interneuron.
Discussion
Morphological and functional aspects of the VLS
The VLS in rodents is distinct from other striatal areas.
Based on morphological criteria, it is a cell-dense region
with fewer fiber bundles than adjacent striatal areas (Fig. 1).
Identification of the VLS is facilitated after combined
staining for AChE enzyme activity and NF immunor-
eactivity (Fig. 1C) and particularly by its strong PV
immunoreactivity (Fig. 1D; Supplementary Fig. 1) as has
been reported [53–57].
Functionally distinct striatal subregions [21] like the
VLS have long been known (see Introduction). Recent
investigations support the potential importance of the VLS
for involuntary orofacial movements. In monkeys with
levodopa-induced dyskinesias (LID) the VLS was the only
striatal region in which serotonin transporter ligand binding
and mean diffusivity could be correlated with the LID-score
[58]. Such data favor the concept of the VLS as a dyskinesia
relevant subfield of the mammalian including primate
striatum. In line with this idea, characteristic afferents dif-
ferentiate the VLS from other striatal areas. Thus, it receives
abundant projections from the temporal lobe, particularly
from the amygdala and the perirhinal and insular cortices
[15, 16, 59]. These cortical areas contain taste regions
[60, 61] and the amygdala is involved with food intake and
the processing of gustatory information [62]. Stimulation of
the amygdala in monkeys results in orofacial movements.
Patients with temporal lobe epilepsy suffer from oral
automatisms and often experience gustatory or olfactory
aurae [63].
The non-cholinergic vGAT/Kv3.3/PV coexpressing
neuron (NGSN) is a novel cell type. So far, very large
neurons in the striatum are known as giant, cholinergic,
TANs [for review see [64]]. The NGSN described here is
non-cholinergic and electrophysiologically distinct from
Table 2 Physiological properties of small, fast-spiking interneurons
(SFS-INs) and the novel giant, fast-spiking interneurons (GFS-INs)
from the ventrolateral striatum as found in the present report.
Intrinsic properties SFS-IN (n
= 4)
GFS-IN (n
= 6)
GCH-INs
Resting membrane
potential (mV)
−74.1 ± 1.7 −72.4 ± 3.6 −57.3 ± ??
Input resistance (MΩ) 64.6 ± 23.6 86.8 ± 30.5 433 ± ??
Membrane time
constant (ms)
7.7 ± 1.6 10.2 ± 3.4 –
Action potential properties
Amplitude (mV) 87.7 ± 7.4 90.7 ± 4.7 –
Threshold (mV) −36.1 ± 4.9 −31.3 ± 6.7 –
Maximal rise/decay ratio 1.8 ± 0.2 2.13 ± 0.46 –
Half-height duration (ms) 0.38 ± 0.08 0.51 ± 0.12 0.82 ± 0.12
Instantaneous
frequency (Hz)
283 ± 26 219 ± 47 –
Data of giant cholinergic interneurons (GCH-INs) are taken from the
literature [55]. Data are given ± SEM.
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TANs. Early Golgi studies demonstrated at least three dis-
tinct types of large neurons within the striatum [65]. The
classical, large neurons with spindle-shaped, triangular or
polygonal perikarya have long, essentially smooth and
sparsely branched dendrites extending mainly from the
poles of the cell (type 1). Other neurons with large round or
oval somata have many, frequently branched, dendrites
originating from all regions of the cell body giving the
neuron a spidery appearance (type 2). Yet other neurons
have very long (up to 700 µm) and essentially smooth
dendrites (type 3). Importantly, the type 3 neurons were
found only in the ventral part of the striatum [66]. The large
neurons described by Bolam et al., however, were retro-
gradely labeled from the ipsilateral substantia nigra [65, 66],
indicating that they are projection neurons. In addition,
Bolam’s neurons were localized in a part of the ventral
striatum, which does not correspond to the VLS. Thus, none
of the three previously described large striatal neurons
appears to be NGSNs reported in the present study.
NGSNs represent a novel subclass of fast-spiking
interneurons restricted to the VLS
In the striatum PV generally is coexpressed with GABA in
medium-sized, aspiny interneurons [67, 68], which account
for but a small percentage of striatal neurons. They are also
known as fast-spiking interneurons [69] and have been
shown to mediate feed-forward inhibition from the cortex
[70]. The electrophysiological properties of PV interneurons
depend on their potassium currents, which are due to
members of the Kv3 family of potassium channels. These
channels permit high-frequency firing, insofar as their vol-
tage dependence and kinetic properties enable a fast reac-
tivation of sodium channels. In addition, Kv3 currents cause
brief action potentials and large after-hypopolarisation
[71–73] thus limiting synaptic depression. PV striatal neu-
rons have attracted much interest, as they apparently are
involved in the generation of gamma oscillations, which
were recently described in the ventral striatum [74].
Some heterogeneity of PV cells is known [70]. One
subtype has a smaller soma and a relatively restricted and
varicose dendritic arborization about 200–300 µm in dia-
meter. The other displays a larger cell body and a more
extended, non-varicose dendritic field of 500–600 µm in
diameter. The latter type roughly resembles our Kv3.3-
positive NGSNs, particularly with respect to the diameter of
dendritic fields. In contrast, NGSNs possess clearly varicose
dendrites (see Fig. 5E). Varicosities on dendrites of PV
neurons are well known [55], supporting the idea that the
non-cholinergic NGSNs described here belong to the group
of PV cells. The larger subtype of PV cells, described in
[70], had non-varicose dendrites, suggesting that they do
not correspond NGSNs.
Irrespective of these issues, NGSNs most likely belong
to the fast-spiking group of neurons. This hypothesis is in
line with the morphology of these cells (see above) and is
additionally supported by our electrophysiological data. The
input resistance (86.8 MΩ) is close to that of fast-spiking
interneurons (Table 2), and their spike width at half
amplitude (0.51 ms) is well below 1 ms, which is the case in
fast-spiking cells. Thus, based on our electrophysiological
data NGSNs do not directly correspond to any of the known
cell types in the striatum, but show strong similarity to the
fast-spiking interneurons (Table 2).
The expression of Kv3.3-containing potassium channels
by VLS NGSNs further supports this idea. In the neocortex,
the coexpression of Kv3.1 and Kv3.3 subunits by some PV-
positive interneurons is common [75], and the formation of
Kv3.1/Kv3.3 heteromeric channels has been documented by
co-immunoprecipitation [51]. In vivo, these cells are able to
respond to sensory stimuli with high-frequency (>600 Hz)
trains of action potentials [76]. NGSNs in the VLS display
Kv3.1 immunoreactivity (Fig. 2E, F) in addition to Kv3.3-
ir, supporting the idea of hetero-oligomeric Kv3.1/Kv3.3
channels in the novel VLS giant neurons.
The presence of NGSNs selectively in the VLS may
provide a link between disturbed motor processes and an
area specifically involved in orofacial movement.
Treatment of patients with schizophrenia with neuro-
leptics is the method of choice and often results in good
outcomes and resocialization of the patients, which
decreases hospitalization and keeps patients in the com-
munity. Long-term treatment, however, is jeopardized by
severe side effects, including orofacial dyskinesias, which
may bring treatment to an undesired end. Orofacial dyski-
nesia is a movement disorder that causes bizarre, rapidly
repetitive movements of face and tongue. Even brief ther-
apy with neuroleptic medications can cause this movement
disorder, which is associated with abnormalities in all major
neurotransmitter systems of the striatum, including GABA
[22–24], acetylcholine [25, 26], and dopamine [27]. But this
fact does not explain the orofacial preference of the motor
side effects following neuroleptic treatment.
Defects of Kv3 channels have been linked to movement
disorders and neurodegeneration. Although Kv3.3 mutant
mice display no overt phenotype, Kv3.3 and Kv3.1 double-
deficient mice show hyperactivity and increased locomotion
and exploratory activity, spontaneous myocloni, and
hypersensitivity to ethanol [37]. Mutations in KCNC3, the
gene encoding the Kv3.3 potassium channel, are associated
with CNS neurodegeneration and developmental deficits in
humans. Especially, spinocerebellar ataxia SCN13 seems to
be linked to Kv3.3 gene mutations [36]. Furthermore, Kv
channels may be involved in the early stages of neurode-
generation in Alzheimer’s disease, consistent with the
hypothesis that mutations of Kv3 family channels are
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sufficient to cause neuronal cell death [37]. NGSNs may
provide a possible missing link, since NGSNs strongly
express the Kv3.3 channel protein and are restricted to the
VLS, an area with strong input from the orofacial sensor-
imotor cortex that repeatedly has been linked to orofacial
dyskinesia [17, 18, 58].
One might ask the question, whether the discovery of
NGSNs could help explicate the pathomechanisms of tardive
dykinesia (TD) or orofacial dyskinesias (OFDs), or whether it
may help to improve therapies. Yes, this may be the case. For
example, the subunit composition of GABA-A receptors may
differ in VLS PV neurons as compared to other striatal areas,
which could permit more specific targeting of benzodiazepine
drugs for the treatment of orofacial dyskinesia. Another
important therapeutic is trihexyphenidyl (Artane), a selective
blocker of the striatal M1-muscarinic receptor [M1Rs; [77],
which mediates excitation of PV neurons [78] and consequent
inhibition of striatal activity. NGSNs may express a higher
amount of M1Ra. Insofar as NGSNs involvement in orofacial
dyskinesia seems likely, Artane may be especially effective in
the treatment of TD/OFD. Whether these pharmacological
insights will bear fruit remains to be seen. What is clear from
the present study is that the well known involvement of the
VLS in TD/OFD is now firmly linked to the selective pre-
sence in VLS of NGSNs, which, because of the dispropor-
tionate role that fast-spiking, PV neurons play in striatal
physiology, may well have an important role in the patho-
genesis of TD/OFD, possibly involving the Kv3.3 channel.
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